Henry Ford Health Henry Ford Health Scholarly Commons

Cardiology Articles

Cardiology/Cardiovascular Research

3-1-2022

Complications and Failure Modes of Polymer-Jacketed Guidewires; Insights From the MAUDE Database

Michael Megaly

Ramez Morcos

Michael Kucharik

Mariam Tawadros

Mir B. Basir Henry Ford Health, mbasir1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles

Recommended Citation

Megaly M, Morcos R, Kucharik M, Tawadros M, Basir MB, Pershad A, Maini B, Khalili H, Alaswad K, and Brilakis ES. Complications and Failure Modes of Polymer-Jacketed Guidewires; Insights From the MAUDE Database. Cardiovasc Revasc Med 2022; 36:132-135.

This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

Authors

Michael Megaly, Ramez Morcos, Michael Kucharik, Mariam Tawadros, Mir B. Basir, Ashish Pershad, Brijeshwar Maini, Houman Khalili, Khaldoon Alaswad, and Emmanouil S. Brilakis



Contents lists available at ScienceDirect

Cardiovascular Revascularization Medicine



Complications and Failure Modes of Polymer-Jacketed Guidewires; Insights From the MAUDE Database



Michael Megaly ^a, Ramez Morcos ^b, Michael Kucharik ^c, Mariam Tawadros ^d, Mir B. Basir ^e, Ashish Pershad ^f, Brijeshwar Maini ^b, Houman Khalili ^b, Khaldoon Alaswad ^e, Emmanouil S. Brilakis ^{g,*}

^a Division of Cardiology, Banner University Medical Center, University of Arizona, Phoenix, AZ, USA

^b Division of Cardiology, Florida Atlantic University, Boca Raton, FL, USA

^c Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA

^d Faculty of Medicine, Ain Shams University, Cairo, Egypt

e Division of Cardiology, Henry Ford Hospital, Detroit, MI, USA

^f Division of Cardiology, Chandler Regional Medical Center, Chandler, AZ, USA

^g Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA

ARTICLE INFO

Article history: Received 4 April 2021 Received in revised form 18 April 2021 Accepted 24 April 2021

Keywords: Polymer-jacketed wires CTO Complex PCI

ABSTRACT

Background: The modes of failure of coronary polymer-jacketed guidewires have received limited study. *Methods:* We queried the Manufacturer and User Facility Device Experience (MAUDE) database between January 2011 and December 2020 for reports on coronary polymer-jacketed guidewires and retrieved 254 reports. *Results:* The most common failure mode was failure of the guidewire to cross (36.2%), followed by guidewire fracture (35%), peeling of the polymer jacket (13.8%), failure to retrieve the guidewire (13.8%), and guidewire unraveling (4.7%). Guidewire fracture was more common with soft (37.3%) compared with stiff (23.8%) guidewires. Failure of retrieval was only reported with soft guidewires (9%). Coronary perforation and dissection occurred in 19.7% and 7.9% of the reports, with more reports with stiff as compared with soft guidewires (45.2% vs. 14.6% for perforation and 21.4% vs. 5.3% for dissection).

Conclusions: The most common failure modes of polymer-jacketed guidewires during percutaneous coronary intervention are failure to cross the lesion, guidewire fracture, and peeling of the polymer jacket. Coronary perforations were more common with stiff whereas wire fracture was more common with soft polymer-jacketed guidewires.

© 2021 Elsevier Inc. All rights reserved.

1. Introduction

Polymer-jacketed guidewires are widely used in percutaneous coronary intervention (PCI) to facilitate advancement through tortuous and severe lesions. They are frequently the first guidewire utilized for crossing chronic total occlusions (CTOs) [1,2]. The first polymer-jacketed guidewire was introduced in 1995 (Choice® PT (Boston Scientific, MA, USA)) followed by multiple guidewires of different tip stiffness by various manufacturers. Polymer-jacketed guidewires may increase the risk of perforation but there is limited data on their limitations and complications. We used the Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) registry

E-mail address: esbrilakis@gmail.com (E.S. Brilakis).

to examine the mode of failure and complications of polymer-jacketed guidewires.

2. Materials and methods

The FDA's MAUDE database is a database of adverse events caused by an approved medical device. The MAUDE is an online database with either mandatory (for manufacturers and device user facilities) or voluntary (for healthcare professionals, patients, and consumers) reporting. We searched the database from January 2011 to December 2020 for reports on coronary polymer-jacketed wires [soft nontapered wires (Whisper, Pilot 50 (Abbott Vascular)), Fielder FC, and Sion black (ASAHI Intecc, Japan)], [soft tapered wires (Fielder XT, Fielder XTA, Fielder XTR (ASAHI Intecc, Japan)), Bandit (Teleflex, USA), and Fighter (Boston Scientific, USA)], and [stiff non-tapered wires (Pilot 200 (Abbott Vascular, USA)), Gladius or Gladius Mongo (Asahi Intecc, Japan), and Raider (Teleflex, USA)].

The database was last accessed on January 2nd, 2021, by two independent reviewers (RM and MM). The MAUDE database is publicly

Abbreviations: MAUDE, Manufacturer and User Facility Device Experience database; PCI, percutaneous coronary intervention.

^{*} Corresponding author at: Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, 920 E 28th Street #300, Minneapolis, MN 55407, USA.

available and de-identified; therefore, no institutional review board approval was required for this study. We compared the mode of failure between soft and stiff polymer-jacketed guidewires and between soft tapered and soft, non-tapered guidewires.

2.1. Outcomes and statistical analysis

The primary outcome of this study was the mode of failure of coronary polymer-jacketed guidewires. Secondary outcomes included clinical consequences of device failure. Categorical variables were described as numbers and percentages and compared using Pearson's chi-square or Fisher's exact tests. A value of p < 0.05 was considered significant, and *p*-values are two-sided where possible. All statistical calculations were performed with IBM SPSS Statistics for Mac, Version 26.0. Armonk, NY: IBM Corp (2020).

3. Results

We found a total of 423 reports during the study period. After excluding non-coronary (n = 145), duplicate and irrelevant cases (n = 24), our final cohort included 254 reports of coronary polymerjacketed guidewire failure. Of those, 42 were for stiff and 212 for soft guidewires (tapered wires n = 76, non-tapered wires n = 136). The study flow chart is shown in Fig. S1. The number of events reported for each category per year is shown in Fig. S2.

3.1. Modes of failure and clinical outcomes

The most common failure mode was failure to cross (36.2%), followed by wire fracture (35%) and peeling of the polymer jacket (13.8%) (Table 1, Fig. 1). Failure to retrieve the guidewire was reported in 13.8%, and guidewire unraveling in 4.7%. Guidewire fracture was more commonly reported with soft (37.3%) as compared with stiff guidewires (23.8%). Retrieval failure was exclusively reported with soft guidewires (9%). There was no difference in wire unraveling or peeling of the polymer jacket between soft and stiff guidewires. Snaring was used in 11.8% of the reports, and the wire was covered by a stent in 10.6%. The wire was left inside the patient in 9.1% of the reports. There was no difference in the mechanisms of failure reported for the tapered vs. non-tapered soft wires (Table S1).

Coronary perforation and dissection occurred in 19.7% and 7.9% of the reports, and were more common with stiff guidewires (45.2% vs. 14.6% and 21.4% vs. 5.3%, respectively). Pericardial effusion occurred in 3.9% of the reports with a higher incidence with stiff wires. Covered stents were used in 49 out of 50 reports of coronary perforation. Surgical intervention was needed in 7.9% of cases, and death occurred in 7.9% of the reports. Failure mechanisms and clinical outcomes of each wire are shown in Table S2.

Specific wire failure modes are shown in Table S3. For the Pilot family, wire fracture represented 41% of Pilot 50 reports and 23% of Pilot 200 reports. Peeling of the polymer jacket was reported in 12.5% of Pilot 50 reports and 23% of Pilot 200 reports. No guidewire unraveling was reported for the Pilot family. There were no reports of coronary perforation with Pilot 50 and only one report with Pilot 200. Within the Fielder family, wire perforation was most common with the Fielder XT (18%) with 0% incidence in the Fielder XTA or XTR. Fracture of the Sion black wire occurred in 38% of the reports and peeling of the polymer jacket in 23.8%. The incidence of coronary perforation with the Sion black guidewire was 19%.

4. Discussion

Our study is the first to report the modes of failure of coronary polymer-jacketed guidewires. The main findings can be summarized as follows: 1) the most commonly reported failure modes of coronary polymer-jacketed guidewires were failure to cross the lesion followed

Table 1

Reports of polymer-jacketed guidewire failure in the MAUDE registry classified according to tip stiffness.

(n = 254) $(n = 212)$ $(n = 42)$ Vessel treatedLAD, $n (%)$ 86 (3.3.9)70 (33)16 (38.1)0.525LCX, $n (%)$ 42 (16.5)38 (17.9)4 (9.5)0.181OM, $n (%)$ 8 (3.1)7(3.3)1 (2.4)0.656LIMA, $n (%)$ 9 (3.5)8 (3.8)1 (2.4)0.656LIMA, $n (%)$ 10 (0.4)1 (0.5)0 (0)0.656Unknown, $n (%)$ 17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, $n (%)$ 144 (56.7)112 (52.8)32 (76.2)0.005CTO, $n (%)$ 96 (37.8)62 (29.2)34 (81)<0.001Tortuous, $n (%)$ 92 (36.2)67 (31.6)9 (21.4)0.188Modes of failureFailure to cross, $n (%)$ 92 (36.2)67 (31.6)25 (59.5)<0.001Wire fracture, $n (%)$ 89 (35)79 (37.3)10 (23.8)0.095Peeling of the polymer jacket, $n (%)$ 35 (13.8)31 (14.6)19 (4.5)<0.001Dissection, $n (%)$ 20 (7.9)11 (5.3)9 (21.4)<0.001Dissection, $n (%)$ 4 (1.6)2 (1.5)0.001 <th></th> <th></th> <th></th> <th></th> <th></th>					
Vessel treated LAD, n (%)86 (33.9) 42 (16.5)70 (33) 38 (17.9)16 (38.1) 4 (9.5)0.181 0.755 $OM, n (%)$ 8 (3.1)7 (3.3)1 (2.4)0.755 $RCA, n (%)$ 91 (35.8)74 (34.9)17 (40.5)0.492 0.452PDA, n (%)9 (3.5)8 (3.8)1 (2.4)0.656 0.442LIMA, n (%)1 (0.4)1 (0.5)0 (0)0.656 0.656Unknown, n (%)17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001		Overall	Soft	Stiff	P-value
LAD, n (%)86 (33.9)70 (33)16 (38.1)0.525LCX, n (%)42 (16.5)38 (17.9)4 (9.5)0.181OM, n (%)8 (3.1)7(3.3)1 (2.4)0.755RCA, n (%)91 (35.8)74 (34.9)17 (40.5)0.492PDA, n (%)9 (3.5)8 (3.8)1 (2.4)0.656LIMA, n (%)1 (0.4)1 (0.5)0 (0)0.656Unknown, n (%)17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001		(n = 254)	(n = 212)	(n = 42)	
LCX, n (%)42 (16.5)38 (17.9)4 (9.5)0.181OM, n (%)8 (3.1)7(3.3)1 (2.4)0.755RCA, n (%)91 (35.8)74 (34.9)17 (40.5)0.492PDA, n (%)9 (3.5)8 (3.8)1 (2.4)0.656LIMA, n (%)1 (0.4)1 (0.5)0 (0)0.656Unknown, n (%)17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001	Vessel treated				
OM, n (%)8 (3.1)7(3.3)1 (2.4)0.755RCA, n (%)91 (35.8)74 (34.9)17 (40.5)0.492PDA, n (%)9 (3.5)8 (3.8)1 (2.4)0.656LIMA, n (%)1 (0.5)0 (0)0.656Unknown, n (%)17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001		86 (33.9)	• •	16 (38.1)	0.525
RCA, n (%)91 (35.8)74 (34.9)17 (40.5)0.492PDA, n (%)9 (3.5)8 (3.8)1 (2.4)0.656LIMA, n (%)1 (0.4)1 (0.5)0 (0)0.656Unknown, n (%)17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001		42 (16.5)		, ,	0.181
PDA, n (\hat{x})9 (3.5)8 (3.8)1 (2.4)0.656LIMA, n (\hat{x})1 (0.4)1 (0.5)0 (0)0.656Unknown, n (\hat{x})17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (\hat{x})144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (\hat{x})96 (37.8)62 (29.2)34 (81)<0.001		. ,		, ,	0.755
LIMA, n (\hat{x})1 (0.4)1 (0.5)0 (0)0.656Unknown, n (\hat{x})17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (\hat{x})144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (\hat{x})96 (37.8)62 (29.2)34 (81)<0.001		• •		, ,	
Unknown, n (%)17 (6.7)14 (6.6)3 (7.1)0.898Lesion characteristicsCalcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001		. ,	. ,	. ,	
Lesion characteristics Calcified, n (%)144 (56.7)112 (52.8)32 (76.2)0.005CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001		. ,	. ,	. ,	
Calcified, n (%)144 (56.7)112 (52.8) $32 (76.2)$ 0.005CTO, n (%)96 (37.8)62 (29.2) $34 (81)$ <0.001	Unknown, n (%)	17 (6.7)	14 (6.6)	3 (7.1)	0.898
Calcified, n (%)144 (56.7)112 (52.8) $32 (76.2)$ 0.005CTO, n (%)96 (37.8)62 (29.2) $34 (81)$ <0.001	Lesion characteristics				
CTO, n (%)96 (37.8)62 (29.2)34 (81)<0.001Tortuous, n (%)76 (29.9)67 (31.6)9 (21.4)0.188Modes of failureFailure to cross, n (%)92 (36.2)67 (31.6)25 (59.5)<0.001		144 (56.7)	112 (52.8)	32 (76.2)	0.005
Tortuous, n (%)76 (29.9)67 (31.6)9 (21.4)0.188Modes of failureFailure to cross, n (%)92 (36.2)67 (31.6)25 (59.5)<0.001				· · ·	
Failure to cross, n (%)92 (36.2)67 (31.6)25 (59.5)<0.001Wire fracture, n (%)89 (35)79 (37.3)10 (23.8)0.095Peeling of the polymer jacket, n (%)35 (13.8)31 (14.6)4 (9.5)0.381Failure of retrieval, n (%)19 (7.5)19 (9)0 (0)0.044Wire unraveling, n (%)12 (4.7)9 (4.2)3 (7.1)0.419ComplicationsPerforation, n (%)50 (19.7)31 (14.6)19 (45.2)<0.001					
Failure to cross, n (%)92 (36.2)67 (31.6)25 (59.5)<0.001Wire fracture, n (%)89 (35)79 (37.3)10 (23.8)0.095Peeling of the polymer jacket, n (%)35 (13.8)31 (14.6)4 (9.5)0.381Failure of retrieval, n (%)19 (7.5)19 (9)0 (0)0.044Wire unraveling, n (%)12 (4.7)9 (4.2)3 (7.1)0.419ComplicationsPerforation, n (%)50 (19.7)31 (14.6)19 (45.2)<0.001				. ,	
Wire fracture, n (%)89 (35)79 (37.3)10 (23.8)0.095Peeling of the polymer jacket, n (%)35 (13.8)31 (14.6)4 (9.5)0.381Failure of retrieval, n (%)19 (7.5)19 (9)0 (0)0.044Wire unraveling, n (%)12 (4.7)9 (4.2)3 (7.1)0.419ComplicationsPerforation, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001					
Peeling of the polymer jacket, n (%)35 (13.8)31 (14.6)4 (9.5)0.381Failure of retrieval, n (%)19 (7.5)19 (9)0 (0)0.044Wire unraveling, n (%)12 (4.7)9 (4.2)3 (7.1)0.419ComplicationsPerforation, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001		• •			
Failure of retrieval, n (%)19 (7.5)19 (9)0 (0)0.044Wire unraveling, n (%)12 (4.7)9 (4.2)3 (7.1)0.044ComplicationsPerforation, n (%)50 (19.7)31 (14.6)19 (45.2)<0.001Dissection, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001Perforation, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001Dissection, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001Perforation, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001Dissection, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001Damponade, n (%)4 (1.6)2 (1.5)0 (0)0.541Mycoratial infarction, n (%)2 (0.8)2 (0.9)0 (0)0.527Stent thrombosis, n (%)1 (0.4)2 (0.8)2 (1.5)0 (0)0.417ManagementWire exchange, n (%)67 (26.4)60 (28.3)7 (16.7)0.11				. ,	
Wire unraveling, n (%)12 (4.7)9 (4.2)3 (7.1)0.419ComplicationsPerforation, n (%)50 (19.7)31 (14.6)19 (45.2)<0.001		• •		. ,	
Complications Perforation, n (%)50 (19.7)31 (14.6)19 (45.2)<0.001Dissection, n (%)20 (7.9)11 (5.3)9 (21.4)<0.001			. ,	. ,	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	wire unraveling, n (%)	12 (4.7)	9 (4.2)	3(7.1)	0.419
Dissection, n ($\%$)20 (7.9)11 (5.3)9 (21.4)<0.001Pericardial effusion, n ($\%$)10 (3.9)6 (2.8)4 (9.5)0.042Hemodynamic collapse, n ($\%$)8 (3.1)4 (1.9)4 (9.5)0.010Tamponade, n ($\%$)4 (1.6)2 (1.5)0 (0)0.541Myocardial infarction, n ($\%$)3 (1.2)1 (0.4)2 (0.8)0.010Stroke, n ($\%$)3 (1.2)1 (0.4)2 (0.8)0.010Wire embolization, n ($\%$)2 (0.8)2 (0.9)0 (0)0.527Stent thrombosis, n ($\%$)1 (0.4)1 (0.5)0 (0)0.656Arrythmia, n ($\%$)2 (0.8)2 (1.5)0 (0)0.417ManagementWire exchange, n ($\%$)67 (26.4)60 (28.3)7 (16.7)0.118Covered stent, n ($\%$)36 (14.2)33 (15.6)3 (7.1)0.305Wire jailed with a stent, n ($\%$)27 (10.6)24 (11.3)3 (7.1)0.305Wire jailed with a stent, n ($\%$)27 (10.6)24 (11.3)3 (7.1)0.422Left inside patient, n ($\%$)27 (10.6)24 (11.3)3 (7.1)0.139Change of CTO technique, n ($\%$)2 (0.83)2 (0.9)0 (0)0.527OutcomeNo adverse events, n ($\%$)194 (76.4)165 (77.8)29 (69)0.221Procedure aborted, n ($\%$)20 (7.9)16 (7.5)4 (9.5)0.664Surgical conversion, n ($\%$)20 (7.9)20 (9.4)0 (0	Complications				
$\begin{array}{c cccc} \mbox{Pericardial effusion, n (\%)} & 10 (3.9) & 6 (2.8) & 4 (9.5) & 0.042 \\ \mbox{Hemodynamic collapse, n (\%)} & 8 (3.1) & 4 (1.9) & 4 (9.5) & 0.010 \\ \mbox{Tamponade, n (\%)} & 4 (1.6) & 2 (1.5) & 0 (0) & 0.541 \\ \mbox{Myocardial infarction, n (\%)} & 4 (1.6) & 4 (1.9) & 0 (0) & 0.370 \\ \mbox{Stroke, n (\%)} & 3 (1.2) & 1 (0.4) & 2 (0.8) & 0.019 \\ \mbox{Wire embolization, n (\%)} & 2 (0.8) & 2 (0.9) & 0 (0) & 0.527 \\ \mbox{Stent thrombosis, n (\%)} & 1 (0.4) & 1 (0.5) & 0 (0) & 0.656 \\ \mbox{Arrythmia, n (\%)} & 2 (0.8) & 2 (1.5) & 0 (0) & 0.417 \\ \mbox{Maagement} \\ \mbox{Wire exchange, n (\%)} & 67 (26.4) & 60 (28.3) & 7 (16.7) & 0.118 \\ \mbox{Covered stent, n (\%)} & 49 (19.3) & 30 (14.2) & 19 (45.2) & <0.001 \\ \mbox{Observation, n (\%)} & 36 (14.2) & 33 (15.6) & 3 (7.1) & 0.153 \\ \mbox{Snare, n (\%)} & 30 (11.8) & 27 (12.7) & 3 (7.1) & 0.305 \\ \mbox{Wire jailed with a stent, n (\%)} & 27 (10.6) & 24 (11.3) & 3 (7.1) & 0.422 \\ \mbox{Left inside patient, n (\%)} & 17 (6.7) & 12 (5.7) & 5 (11.9) & 0.139 \\ \mbox{Change of CTO technique, n (\%)} & 20 (0.8) & 2 (0.9) & 0 (0) & 0.527 \\ \mbox{Outcome} \\ \mbox{No adverse events, n (\%)} & 194 (76.4) & 165 (77.8) & 29 (69) & 0.221 \\ \mbox{Procedure aborted, n (\%)} & 20 (7.9) & 16 (7.5) & 4 (9.5) & 0.664 \\ \mbox{Surgical conversion, n (\%)} & 20 (7.9) & 20 (9.4) & 0 (0) & 0.038 \\ \end{tabular}$	Perforation, n (%)	50 (19.7)	31 (14.6)	19 (45.2)	< 0.001
Hemodynamic collapse, n (%)8 (3.1)4 (1.9)4 (9.5)0.010Tamponade, n (%)4 (1.6)2 (1.5)0 (0)0.541Myocardial infarction, n (%)4 (1.6)4 (1.9)0 (0)0.370Stroke, n (%)3 (1.2)1 (0.4)2 (0.8)0.019Wire embolization, n (%)2 (0.8)2 (0.9)0 (0)0.527Stent thrombosis, n (%)1 (0.4)1 (0.5)0 (0)0.656Arrythmia, n (%)2 (0.8)2 (1.5)0 (0)0.417ManagementWire exchange, n (%)67 (26.4)60 (28.3)7 (16.7)0.118Covered stent, n (%)49 (19.3)30 (14.2)19 (45.2)<0.001	Dissection, n (%)	20 (7.9)	11 (5.3)	9 (21.4)	< 0.001
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Pericardial effusion, n (%)	10 (3.9)	6 (2.8)	4 (9.5)	0.042
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Hemodynamic collapse, n (%)	8 (3.1)	4 (1.9)	4 (9.5)	0.010
Stroke, n (%)3 (1.2)1 (0.4)2 (0.8)0.019Wire embolization, n (%)2 (0.8)2 (0.9)0 (0)0.527Stent thrombosis, n (%)1 (0.4)1 (0.5)0 (0)0.656Arrythmia, n (%)2 (0.8)2 (1.5)0 (0)0.417Management 2 (0.8)2 (1.5)0 (0)0.417Maragement 30 (14.2)19 (45.2)<0.001		4 (1.6)		0(0)	0.541
Wire embolization, n (%)2 (0.8)2 (0.9)0 (0)0.527Stent thrombosis, n (%)1 (0.4)1 (0.5)0 (0)0.656Arrythmia, n (%)2 (0.8)2 (1.5)0 (0)0.417ManagementWire exchange, n (%)67 (26.4)60 (28.3)7 (16.7)0.118Covered stent, n (%)49 (19.3)30 (14.2)19 (45.2)<0.001		. ,		. ,	0.370
Stent thrombosis, n ($\%$)1 (0.4)1 (0.5)0 (0)0.656Arrythmia, n ($\%$)2 (0.8)2 (1.5)0 (0)0.417ManagementWire exchange, n ($\%$)67 (26.4)60 (28.3)7 (16.7)0.118Covered stent, n ($\%$)49 (19.3)30 (14.2)19 (45.2)<0.001		. ,	. ,	. ,	
Arrythmia, n (%)2 (0.8)2 (1.5)0 (0)0.417ManagementWire exchange, n (%) $67 (26.4)$ $60 (28.3)$ 7 (16.7)0.118Covered stent, n (%) $49 (19.3)$ $30 (14.2)$ $19 (45.2)$ <0.001		. ,	. ,		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$. ,	. ,	. ,	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Arrythmia, n (%)	2 (0.8)	2 (1.5)	0(0)	0.417
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Management				
$\begin{array}{cccc} \mbox{Covered stent, n (\%)} & 49 (19.3) & 30 (14.2) & 19 (45.2) & <0.001 \\ \mbox{Observation, n (\%)} & 36 (14.2) & 33 (15.6) & 3 (7.1) & 0.153 \\ \mbox{Snare, n (\%)} & 30 (11.8) & 27 (12.7) & 3 (7.1) & 0.305 \\ \mbox{Wire jailed with a stent, n (\%)} & 27 (10.6) & 24 (11.3) & 3 (7.1) & 0.422 \\ \mbox{Left inside patient, n (\%)} & 23 (9.1) & 21 (9.9) & 2 (4.8) & 0.289 \\ \mbox{Unknown, n (\%)} & 17 (6.7) & 12 (5.7) & 5 (11.9) & 0.139 \\ \mbox{Change of CTO technique, n (\%)} & 2 (0.83) & 2 (0.9) & 0 (0) & 0.527 \\ \hline \nbegar{tabular}{} \\ \mbox{Not adverse events, n (\%)} & 194 (76.4) & 165 (77.8) & 29 (69) & 0.221 \\ \mbox{Procedure aborted, n (\%)} & 20 (7.9) & 16 (7.5) & 4 (9.5) & 0.664 \\ \mbox{Surgical conversion, n (\%)} & 20 (7.9) & 20 (9.4) & 0 (0) & 0.038 \\ \hline \end{tabular}$		67 (26.4)	60 (28.3)	7 (16.7)	0.118
$\begin{array}{ccccc} Observation, n (\%) & 36 (14.2) & 33 (15.6) & 3 (7.1) & 0.153 \\ Snare, n (\%) & 30 (11.8) & 27 (12.7) & 3 (7.1) & 0.305 \\ Wire jailed with a stent, n (\%) & 27 (10.6) & 24 (11.3) & 3 (7.1) & 0.422 \\ Left inside patient, n (\%) & 23 (9.1) & 21 (9.9) & 2 (4.8) & 0.289 \\ Unknown, n (\%) & 17 (6.7) & 12 (5.7) & 5 (11.9) & 0.139 \\ Change of CTO technique, n (\%) & 2 (0.83) & 2 (0.9) & 0 (0) & 0.527 \\ \hline \\ Outcome \\ No adverse events, n (\%) & 194 (76.4) & 165 (77.8) & 29 (69) & 0.221 \\ Procedure aborted, n (\%) & 20 (7.9) & 16 (7.5) & 4 (9.5) & 0.664 \\ Surgical conversion, n (\%) & 20 (7.9) & 20 (9.4) & 0 (0) & 0.038 \\ \hline \end{array}$		49 (19.3)		19 (45.2)	< 0.001
Wire jailed with a stent, n (%) 27 (10.6) 24 (11.3) 3 (7.1) 0.422 Left inside patient, n (%) 23 (9.1) 21 (9.9) 2 (4.8) 0.289 Unknown, n (%) 17 (6.7) 12 (5.7) 5 (11.9) 0.139 Change of CTO technique, n (%) 2 (0.83) 2 (0.9) 0 (0) 0.527 Outcome 194 (76.4) 165 (77.8) 29 (69) 0.221 Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038			33 (15.6)	3 (7.1)	0.153
Left inside patient, n (%) 23 (9.1) 21 (9.9) 2 (4.8) 0.289 Unknown, n (%) 17 (6.7) 12 (5.7) 5 (11.9) 0.139 Change of CTO technique, n (%) 2 (0.83) 2 (0.9) 0 (0) 0.527 Outcome No adverse events, n (%) 194 (76.4) 165 (77.8) 29 (69) 0.221 Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038	Snare, n (%)	30 (11.8)	27 (12.7)	3 (7.1)	0.305
Unknown, n (%) 17 (6.7) 12 (5.7) 5 (11.9) 0.139 Change of CTO technique, n (%) 2 (0.83) 2 (0.9) 0 (0) 0.527 Outcome No adverse events, n (%) 194 (76.4) 165 (77.8) 29 (69) 0.221 Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038	Wire jailed with a stent, n (%)	27 (10.6)	24 (11.3)	3 (7.1)	0.422
Change of CTO technique, n (%) 2 (0.83) 2 (0.9) 0 (0) 0.527 Outcome	Left inside patient, n (%)	23 (9.1)	21 (9.9)	2 (4.8)	0.289
Outcome 194 (76.4) 165 (77.8) 29 (69) 0.221 Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038	Unknown, n (%)	17 (6.7)	12 (5.7)	5 (11.9)	0.139
No adverse events, n (%) 194 (76.4) 165 (77.8) 29 (69) 0.221 Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038	Change of CTO technique, n (%)	2 (0.83)	2 (0.9)	0(0)	0.527
No adverse events, n (%) 194 (76.4) 165 (77.8) 29 (69) 0.221 Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038	Outcome				
Procedure aborted, n (%) 20 (7.9) 16 (7.5) 4 (9.5) 0.664 Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038		194 (76.4)	165 (77.8)	29 (69)	0.221
Surgical conversion, n (%) 20 (7.9) 20 (9.4) 0 (0) 0.038		. ,	• •	. ,	
				. ,	
	e	20 (7.9)	11 (5.2)	9 (21.4)	

LAD = left anterior descending artery; LCX = left circumflex artery; OM = obtuse marginal artery; RCA = right coronary artery; PDA = posterior descending artery; LIMA = left internal mammary artery; CTO = chronic total occlusion.

by guidewire fracture and peeling of the polymer jacket, and 2) as compared with soft guidewires stiff guidewires were often associated with coronary perforation, dissection, pericardial effusion, and need for covered stents.

Polymer-jacketed guidewires are frequently used in complex PCI, as they are lubricious and can often negotiate significant tortuosity and advance through highly stenosed or 100% lesions. [3] In this study, they were further categorized as stiff or soft wires. Stiff polymer-jacketed guidewires have high tip-load with high penetration power. They are non-tapered and mainly used for CTO PCI. The soft polymer-jacketed wires are designed to track microchannels and navigate tortuosity, and are often the first guidewires used for antegrade CTO crossing. They can be either tapered or non-tapered.

In our analysis, the most common mode of failure was failure to cross the lesion, which is not an adverse event. Failure to cross was reported in 59.5% of the stiff wires reports and 31.6% in the soft wires reports. Failure to cross is not unexpected and is likely related to high lesion complexity (76.2% calcified lesions, 81% CTOs).




Fig. 1. Failure modes of coronary polymer-jacketed wires as reported to the MAUDE registry.

Guidewire fracture occurred in 35% of the reports and was more common with soft guidewires. It may be related to aggressive guidewire manipulation (polymer-jacketed guidewires are often knuckled to facilitate extraplaque CTO crossing). Sometimes leaving the guidewire fragment within the coronary artery and covering it with a stent may be safer than attempting retrieval, which however may be necessary if the guidewire fragment fratgprotrudes into the aorta [4].

Given the nature of the polymer-jacketed wires, abrasive surfaces such as severe calcification at bends and stent struts jailing polymerjacketed wires can strip the polymer of the guidewire. In our analysis, peeling of the polymer jacket was reported in 13.8% of cases. The peeled off polymer may embolize into the microvasculature, causing myocardial infarction [5]. Pan et al. reported that during bifurcation stenting, jailed polymer-jacketed wires were more resistant to retrieval damage and more efficient in crossing the side branch ostium than nonpolymer-jacketed wires [6]. The question of whether to jail polymerjacketed vs. non-polymer-jacketed wires during bifurcation stenting is beyond the scope of our study.

In our analysis, the occurrence of coronary perforation or dissection was high with the use of stiff polymer-jacketed wires (45.2% of the reports). In contrast, perforation with soft wires was reported in 14.6%. Although polymer jacketed guidewires are considered safer than non-polymer jacketed stiff guidewires they can still cause coronary perforations, especially if a balloon or microcatheter is advanced over the guidewire after it exits from the vessel architecture [7,8]. The perforation site was not consistently reported, and therefore, could not be analyzed. In our analysis, covered stents were used in 49 out of 50 reports of coronary perforations caused by polymer-jacketed wires. Use of orthogonal projections to verify the guidewire course before advancing equipment over it is critical. The polymer-jacketed guidewire should be replaced by a workhose guidewire after successful crossing to minimize the risk of distal coronary perforation.

4.1. Limitations

Our study is limited by selection bias resulting from the retrospective analysis from the MAUDE and selective optional reporting by healthcare professionals. Second, the incidence of each device's mode of failure cannot be determined as the study lacks a denominator. Third, details on the sites of perforation (e.g., vessel body, distal vessel, etc.) and microcatheter-induced perforations are not consistently reported and therefore could not be analyzed. Finally, a correlation between the device failure and clinical adverse events cannot be accurately determined (e.g., coronary perforation requiring covered stents can be due to microcatheter advancement rather than the wire itself).

4.2. Conclusions

The most common failure modes of polymer-jacketed guidewires during percutaneous coronary intervention are failure to cross the lesion, guidewire fracture, and peeling of the polymer jacket. Coronary perforations were more often reported with stiff polymer-jacketed guidewires.

CRediT authorship contribution statement

Michael Megaly: conceptualization, Development or design of methodology, statistical analysis, writing the initial draft.

Ramez Morcos: data curation, development or design of methodology.

Michael Kucharik: data curation.

Mariam Tawadros: data curation.

Mir B. Basir: critical review, commentary, and revision.

Ashish Pershad: critical review, commentary, and revision.

Brijeshwar Maini: critical review, commentary, and revision.

Houman Khalili: critical review, commentary, and revision.

Khaldoon Alaswad: critical review, commentary, and revision.

Emmanouil S. Brilakis: Conceptualization oversight and leadership responsibility for the research activity planning and execution. critical review, commentary, and revision.

Funding

None.

Declaration of competing interest

Khaldoon Alaswad: consulting/speaker honoraria from Boston Scientific, Cardiovascular Systems Inc., Abbott Vascular, Teleflex.

Mir Basir: Consulting/Speaker Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, Zoll.

Emmanouil Brilakis: consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Ebix, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; research support from Regeneron and Siemens; owner, Hippocrates LLC; shareholder: MHI Ventures, Cleerly Health.

H Khalili: Abbott vascular speaker bureau.

All other authors have nothing to disclose.

Acknowledgments

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi. org/10.1016/j.carrev.2021.04.027.

References

 Rossi JE, Nair R, Ellis SG, Kapadia SR, Khatri JJ. Use of polymer-jacketed, tapered-tip, low-force guidewires with composite-core, dual-coil design as part of the antegrade approach to coronary chronic total occlusions. J Invasive Cardiol. 2020;32:161–8.

- [2] Brilakis ES, Grantham JA, Rinfret S, Wyman RM, Burke MN, Karmpaliotis D, et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv. 2012;5:367–79.
- [3] Buller CE. Coronary guidewires for chronic total occlusion procedures: function and design. Interv Cardiol. 2013;5:533.
- [4] Danek BA, Karatasakis A, Brilakis ES. Consequences and treatment of guidewire entrapment and fracture during percutaneous coronary intervention. Cardiovasc Revasc Med. 2016;17:129–33.
- [5] Chatterjee A, White JS, Hashim T, Leesar MA. Jailing polymer jacketed guide-wires during bifurcation coronary interventions is associated with procedural myocardial infarction. World J Cardiol. 2017;9:442–7.
- [6] Pan M, Ojeda S, Villanueva E, Chavarria J, Romero M, Suarez de Lezo J, et al. Structural damage of jailed guidewire during the treatment of coronary bifurcation lesions: a microscopic randomized trial. J Am Coll Cardiol Intv. 2016;9:1917–24.
- [7] Shaukat A, Tajti P, Sandoval Y, Stanberry L, Garberich R, Nicholas Burke M, et al. Incidence, predictors, management and outcomes of coronary perforations. Catheter Cardiovasc Interv. 2019;93:48–56.
- [8] Eggebrecht H, Ritzel A, von Birgelen C, Schermund A, Naber C, Böse D, et al. Acute and long-term outcome after coronary artery perforation during percutaneous coronary interventions. Z Kardiol. 2004;93:791–8.